Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of NM2AI can be broken down into several components which progressively intensify proportional to dosage.
The general head space of NM2AI is described by many as one of mental stimulation, increased focus, and euphoria. It contains a large number of typical stimulant cognitive effects. Although negative side effects are usually mild at low to moderate doses, they become increasingly likely to manifest themselves with higher amounts or extended usage. This particularly holds true during the offset of the experience.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Chronic use is considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence. Compulsive redosing has been reported. When addiction develops, cravings and withdrawal effects may occur upon cessation.
Withdrawal effects are mentioned in the context of addiction, but specific physical dependence characteristics have not been documented for this substance.
The exact toxic dosage is unknown. Toxicity and long-term health effects have not been studied in any scientific context due to the substance's very limited history of human usage.
As with other stimulants, abuse at high dosages for prolonged periods can potentially result in stimulant psychosis presenting with paranoia, hallucinations, or delusions. Based on data from related amphetamine-type stimulants, approximately 5-15% of individuals who develop stimulant psychosis may fail to recover completely, though antipsychotic medications effectively resolve symptoms of acute episodes.
Seizure risk from NM-2-AI alone has not been documented, though combination with certain substances may increase seizure risk.
NM-2-AI is a novel stimulant belonging to the aminoindane chemical class. Structurally, it represents a rigid analogue of methamphetamine and shares close chemical relationships with other aminoindane compounds such as 2-AI and MDAI. The substance emerged on the online research chemical market as a designer drug, where it has been sold through various vendors. It remains a lesser-known compound compared to its aminoindane relatives, with limited documentation of its history or cultural significance beyond its presence in the contemporary designer drug landscape.
Controlled under the New Psychoactive Substances Act since November 26, 2016. Production and import with intent to distribute, administration to others, and trading are punishable offenses. Possession is technically illegal but not subject to criminal penalties.
Production, supply, and import are prohibited under the Psychoactive Substances Act, which came into effect on May 26, 2016.
Specifically named as a controlled substance under Schedule E of Swiss narcotics legislation.
15 sources cited
